Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
368.92
+0.50 (0.14%)
Nov 4, 2024, 4:00 PM EST - Market closed
Bio-Rad Laboratories Revenue
Bio-Rad Laboratories had revenue of $649.73M in the quarter ending September 30, 2024, with 2.79% growth. This brings the company's revenue in the last twelve months to $2.58B, down -5.15% year-over-year. In the year 2023, Bio-Rad Laboratories had annual revenue of $2.67B, down -4.67%.
Revenue (ttm)
$2.58B
Revenue Growth
-5.15%
P/S Ratio
4.06
Revenue / Employee
$321,321
Employees
8,030
Market Cap
10.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.67B | -130.99M | -4.67% |
Dec 31, 2022 | 2.80B | -120.30M | -4.12% |
Dec 31, 2021 | 2.92B | 376.92M | 14.81% |
Dec 31, 2020 | 2.55B | 233.97M | 10.12% |
Dec 31, 2019 | 2.31B | 22.24M | 0.97% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG | 20.80B |
Smith & Nephew | 5.64B |
Encompass Health | 5.22B |
Catalent | 4.38B |
AptarGroup | 3.57B |
Bio-Rad Laboratories | 2.58B |
Globus Medical | 2.24B |
Exelixis | 2.08B |
BIO News
- 4 days ago - Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference - Business Wire
- 5 days ago - Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit - Reuters
- 5 days ago - Bio-Rad Reports Third-Quarter 2024 Financial Results - Business Wire
- 21 days ago - Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Business Wire
- 2 months ago - Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 - PRNewsWire
- 2 months ago - Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference - Business Wire
- 2 months ago - Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer - Business Wire